tirzepatide spray HypoSpray® Tirzepatide HypoSpray®

Light pressure with a clean tissue is acceptable if there is minor bleeding

SURMOUNT-1 Tirzepatide The pivotal tirzepatide trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks

Retatrutide pharmacology that affects dosing decisions Understanding why the doses are what they are helps you make smarter decisions about your protocol

The effect of GLP-1R agonists liraglutide and exendin-4 was examined in vitro on LOVO, CA-77, MCF-7, MDA-MB-231, KPL-1, MB-468, 4TI, BT483, ZR751, LNCap, PC3, ALVA-41, DU145, LNCap, PANC-1, MiaPaCa-2, PANC, CT26, SKOV3, OVCAR3, OVCAR4, A2780, and ES-2 cell lines that are expressed in several cancers including colorectal, pancreatic, thyroid, breast, prostate, ovarian, and colon (Table 1)